Pacira | PCRX - Interest Expense On Debt

Stock Price
24.51
Daily Change
-0.85 -3.35%
Monthly
4.34%
Yearly
-4.70%
Q2 Forecast
23.99

Pacira reported $3.89M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Assertio Holdings USD 758K 1000 Jun/2024
Astellas Pharma JPY 3.91B 320M Mar/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
Cara Therapeutics 39.02M 4.73M Sep/2025
Coherus Biosciences USD 2.25M 76K Dec/2025
Heron Therapeutics USD 600K 100K Dec/2024
Ironwood Pharmaceuticals USD 8.74M 506K Dec/2024
J&J USD 43M 25M Mar/2026
Ligand Pharmaceuticals USD 910K 243K Sep/2025
Nektar Therapeutics USD 9.77M 3.75M Dec/2025
Novo Nordisk DKK 1.53B 3.43B Sep/2025
Omeros USD 4.05M 5.16M Sep/2024
Pacira USD 3.89M 387K Dec/2025
Perrigo USD 10.08B 10.04B Sep/2025
Pfizer USD 711M 59M Dec/2025
Supernus Pharmaceuticals USD 910K 278K Jun/2023
Teva Pharmaceutical Industries USD 220M 17M Dec/2025
Xeris Pharmaceuticals USD 7.15M 115K Dec/2025
Xoma USD 3.4M 150K Jun/2024
Zoetis USD 57M 1000K Dec/2025